Sprint Bioscience AB (SPRINT) - Total Liabilities

Latest as of September 2025: Skr15.37 Million SEK ≈ $1.65 Million USD

Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has total liabilities worth Skr15.37 Million SEK (≈ $1.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Sprint Bioscience AB generate cash to assess how effectively this company generates cash.

Sprint Bioscience AB - Total Liabilities Trend (2011–2024)

This chart illustrates how Sprint Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. Check Sprint Bioscience AB (SPRINT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Sprint Bioscience AB Competitors by Total Liabilities

The table below lists competitors of Sprint Bioscience AB ranked by their total liabilities.

Company	Country	Total Liabilities
Touch Ventures Ltd AU:TVL	Australia	AU$202.00K
Maniker KO:027740	Korea	₩115.99 Billion
Golden Heaven Group Holdings Ltd. Ordinary Shares NASDAQ:GDHG	USA	$10.80 Million
Cayman Tung Ling Co Ltd TWO:2924	Taiwan	NT$485.00 Million
Centric Holdings S.A AT:CENTR	Greece	€11.16 Million
Fortune Indonesia Tbk JK:FORU	Indonesia	Rp5.72 Billion
Anli International Co Ltd TWO:5223	Taiwan	NT$1.45 Billion
MDX Public Company Limited BK:MDX	Thailand	฿704.58 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Sprint Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sprint Bioscience AB market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.13	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.54	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.72	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sprint Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sprint Bioscience AB (2011–2024)

The table below shows the annual total liabilities of Sprint Bioscience AB from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr32.78 Million ≈ $3.53 Million	-5.26%
2023-12-31	Skr34.60 Million ≈ $3.72 Million	+274.73%
2022-12-31	Skr9.23 Million ≈ $993.73K	+6.35%
2021-12-31	Skr8.68 Million ≈ $934.43K	-64.20%
2020-12-31	Skr24.25 Million ≈ $2.61 Million	+194.82%
2019-12-31	Skr8.23 Million ≈ $885.36K	-62.68%
2018-12-31	Skr22.05 Million ≈ $2.37 Million	+198.09%
2017-12-31	Skr7.40 Million ≈ $795.93K	-64.83%
2016-12-31	Skr21.03 Million ≈ $2.26 Million	-18.54%
2015-12-31	Skr25.81 Million ≈ $2.78 Million	+434.79%
2014-12-31	Skr4.83 Million ≈ $519.44K	+17.47%
2013-12-31	Skr4.11 Million ≈ $442.19K	+28.24%
2012-12-31	Skr3.20 Million ≈ $344.81K	+329.45%
2011-12-31	Skr746.09K ≈ $80.29K	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$35.31 Million

Skr328.15 Million SEK

Market Cap Rank

#23150 Global

#441 in Sweden

Share Price

Skr3.11

Change (1 day)

-3.42%

52-Week Range

Skr0.41 - Skr4.04

All Time High

Skr47.75